OKYO Pharma Limited (OKYO) Financial Ratios
18 years of historical data (2008–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: N/A
ROE
↓
N/A
—
5yr avg: -1076.5%
30Y Low-131%·High44%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
OKYO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
OKYO Pharma Limited currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $66M | $50M | $44M | $37M | — | — | — | — | — | — | — |
| Enterprise Value | $64M | $49M | $43M | $36M | — | — | — | — | — | — | — |
| P/E Ratio → | -13.50 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
OKYO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
OKYO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -2968.6% | -131.4% | -129.5% | -1595.3% | -1469.4% | — | — | -2.5% |
| ROA | -180.4% | -180.4% | -498.9% | -279.3% | -95.3% | -87.2% | -227.2% | -644.2% | — | — | -2.5% |
| ROIC | — | — | — | — | -1894.5% | — | — | -17587.1% | — | — | -3.0% |
| ROCE | — | — | — | -2927.3% | -149.6% | -156.8% | -1381.5% | -1362.5% | — | — | -3.3% |
OKYO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $2M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.02 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | -0.92 | -1.28 | — | -1.88 | — | — | -0.16 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | 0.00 | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -8.14 | -8.14 | -14.90 | -135.36 | — | -3680.63 | -1313.88 | — | — | — | — |
Net cash position: cash ($2M) exceeds total debt ($0)
OKYO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.40x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 0.72x to 0.40x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.40 | 0.40 | 0.21 | 0.72 | 3.17 | 4.09 | 0.80 | 1.78 | — | — | 29.62 |
| Quick Ratio | 0.40 | 0.40 | 0.21 | 0.69 | 3.18 | 4.09 | 0.80 | 1.78 | — | — | 29.62 |
| Cash Ratio | 0.17 | 0.17 | 0.11 | 0.56 | 2.00 | 4.04 | 0.33 | 1.47 | — | — | 28.28 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | 0.02 | — | — | 0.02 | — | 384.88 | — | 1.74 | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
OKYO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
OKYO Pharma Limited does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Shares Outstanding | — | $39M | $29M | $22M | $15M | $10M | $9M | $8M | $6M | $6M | $6M |
Peer Comparison
Compare OKYO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 OKYOYou | $66M | -13.5 | — | — | — | — | — | — | — |
 LNTH | $6B | 26.7 | 14.6 | 16.7 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 SGHT | $286M | -7.1 | — | — | 86.2% | -48.0% | -50.7% | -274.4% | — |
 AVXL | $289M | -5.8 | — | — | — | — | -43.1% | — | — |
 ALDX | $104M | -1.8 | — | — | — | — | -58.5% | -369.4% | — |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 TARS | $3B | -40.2 | — | — | 93.2% | -15.7% | -23.4% | -23.4% | — |
 PRPH | $5M | -0.0 | — | — | -2.2% | -570.6% | -188.1% | -59.4% | — |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 18 years · Updated daily
See OKYO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs OKYO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare OKYO vs LNTH
Side-by-side business, growth, and profitability comparison vs Lantheus Holdings, Inc..
Start ComparisonOKYO — Frequently Asked Questions
Quick answers to the most common questions about buying OKYO stock.
What is OKYO Pharma Limited's P/E ratio?
OKYO Pharma Limited's current P/E ratio is -13.5x. This places it at the 50th percentile of its historical range.
Is OKYO stock overvalued?
Based on historical data, OKYO Pharma Limited is trading at a P/E of -13.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.